The Painful Story Of Dry Eye Disease
Dry Eye might sound like something most can solve with OTC eye drops, but in reality 20% of the adult population worldwide report real quality of life impairment associated with this modern day epidemic. DED is no small irritation, for millions of patients it’s a daily agony of light sensitivity, stabbing pain, gritty sand sensation, blurry vision, and in some cases can lead to severe vision impairment.
People in the US use pharmaceutical treatments,
usually with very low compliance or efficacy
Of ophthalmologists desire better treatment options
Epitech – The promise of
long-lasting, affordable relief
Epitech’s innovative non-invasive ocular neurostimulation therapy is designed to treat the entire ocular surface and tear film, for long-lasting relief of dry eye symptoms.
Epitech’s proprietary technology is based on neurostimulation by targeted magnetic fields, resulting in the reinforcement of the structural integrity of the ocular surface. The procedure is well-tolerated, making it easy for patients to comply with protocol.
Epitech is currently in a multi-center pilot study with excellent results for the first patients. The company has a solid intellectual property portfolio in the field of ocular neurostimulation and is led by a seasoned team of tech and clinical veterans, with leading KOLs in advisory roles.
Initial Results Show Corenal Staining Improvement Over Time
Efficiently Relieving Dry Eye Symptoms
dry eye relief
Easy to comply
Expanding Treatment Opportunities
Can be administered regardless
of the cause of DED, expanding treatable patient populations
In-office treatment performed by technicians
EpiTech Mag Ltd. was incorporated in Israel in Feb. 2015 out of the offices of the Terra Labs Incubator